Caligan Partners LP bought $318K of Liquidia (LQDA)
Executed May 19, disclosed May 21, 1 day later.
Over the 21 trading sessions from the disclosed entry session (May 20), the stock returned +18.4% (delay-adjusted); from the execution session (May 19), +20.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Caligan Partners LP (Director) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in Liquidia Corporation (LQDA). Across 1 priced purchase filing, the average 21-session return was +20.5% from execution and +18.4% from disclosure (delay-adjusted; derived). The largest single filing was $318K of LQDA (5,300 sh × $59.98, as filed), executed May 19.
Healthcare · Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary dis…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→